DOCSLIB.ORG

Cardiovascular Diseases Genetic Testing Program Information

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Cardiovascular Diseases Genetic Testing Program Description: Congenital Heart Disease Panels We offer comprehensive gene panels designed to • Congenital Heart Disease Panel (187 genes) diagnose the most common genetic causes of hereditary • Heterotaxy Panel (114 genes) cardiovascular diseases. Testing is available for congenital • RASopathy/Noonan Spectrum Disorders Panel heart malformation, cardiomyopathy, arrythmia, thoracic (31 genes) aortic aneurysm, pulmonary arterial hypertension, Marfan Other Panels syndrome, and RASopathy/Noonan spectrum disorders. • Pulmonary Arterial Hypertension (PAH) Panel Hereditary cardiovascular disease is caused by variants in (20 genes) many different genes, and may be inherited in an autosomal dominant, autosomal recessive, or X-linked manner. Other Indications: than condition-specific panels, we also offer single gene Panels: sequencing for any gene on the panels, targeted variant • Confirmation of genetic diagnosis in a patient with analysis, and targeted deletion/duplication analysis. a clinical diagnosis of cardiovascular disease Tests Offered: • Carrier or pre-symptomatic diagnosis identification Arrythmia Panels in individuals with a family history of cardiovascular • Comprehensive Arrhythmia Panel (81 genes) disease of unknown genetic basis • Atrial Fibrillation (A Fib) Panel (28 genes) Gene Specific Sequencing: • Atrioventricular Block (AV Block) Panel (7 genes) • Confirmation of genetic diagnosis in a patient with • Brugada Syndrome Panel (21 genes) cardiovascular disease and in whom a specific gene • Catecholaminergic Polymorphic Ventricular Tachycardia associated diagnosis is suspected (CPVT) Panel (11 genes) Variant Specific Analysis: • Long QT Syndrome Panel (19 genes) • Pre-symptomatic testing of at-risk siblings and parents for medical management • Short QT Syndrome Panel (6 genes) • Carrier identification in individuals in whom specific Connective Tissue Disorders Panel variant(s) have been identified in the proband • Thoracic Aortic Aneurysm Panel (49 genes) • Prenatal diagnosis of an at-risk fetus, after • Marfan Syndrome and MFS Related Disorders Panel confirmation of variant(s) in the parent(s) and by (3 genes) prior arrangement only Cardiomyopathy Panels Deletion/Duplication Analysis: • Comprehensive Cardiomyopathy Panel (135 genes) • Completion of the diagnostic evaluation in a patient • Arrhythmogenic Right Ventricular Cardiomyopathy with a clinical diagnosis of cardiovascular disease (ARVC) Panel (18 genes) who has had a negative panel or who is heterozygous • Dilated Cardiomyopathy (DCM) Panel (73 genes) for a variant in a gene associated with an autosomal • Hypertrophic Cardiomyopathy (HCM) Panel (98 genes) recessive condition. • Left Ventricular Noncompaction (LVNC) Panel (36 genes) • Restrictive Cardiomyopathy (RCM) Panel (9 genes) Laboratory of Genetics and Genomics CLIA#: 36D0656333 Phone: (513) 636-4474 Fax: (513) 636-4373 Email: [email protected] www.cincinnatichildrens.org/genetics Specimen: Test Sensitivity: Provide at least 3 mL of whole blood in a lavender top Analytical Sensitivity: The sensitivity of DNA sequencing (EDTA) tube or saliva in an Oragene saliva kit. Please call is over 99% for the detection of nucleotide base changes, the lab at 513-636-4474 for a free saliva collection kit. small deletions and insertions in the regions analyzed. Label the tube with the patient’s name, birth date, and Sequencing Test Limitations: Pathogenic variants may date of collection. Alternatively, 10 mcg of high quality be present in a portion of the genes not covered by this DNA may be submitted. test or in regions with suboptimal data due to For prenatal samples, at least 20 mL of amniotic fluid or at homologous issue, polynucleotides, or nucleotide least 30 mg chorionic villi or 2 flasks of cultured cells is repeats, and therefore may not be identified. Thus, the needed. 3 mL of maternal blood in lavender top (EDTA) absence of identified pathogenic variants does not tube is needed for maternal cell contamination studies. exclude the possibility of a genetic etiology for the patient’s symptoms.•Certain types of mutations are not Testing Methodology: detected. Only single base pair changes or small Panels: Our panels utilize Exome Sequencing (ES) insertions or deletions of DNA are detected. Large technology to detect variants in predefined lists of deletions, duplications, or rearrangements, clinically relevant genes to identify inherited forms of mitochondrial genome mutations, repeat expansions, cardiovascular diseases. Our panels use the Human low level mosaicism and many epigenetic defects may Comprehensive Exome kit from Twist Bioscience to not be detected by this test. capture the exonic regions of genes from the genomic Regions of Homology DNA extracted from the patient. Targeted regions are These gene regions with homology may generate sequenced using the Illumina sequencing system with suboptimal data with potential false negative results. paired-end reads. Sequence reads are aligned to reference TRANSCRIPT genome (build UCSC hg19). Variants within exons and GENE EXON CHROM EXON_START EXON_END ARMC4 NM_001290020 9 10 28257851 28257947 flanking sequences are identified and evaluated by a CDC42 NM_001791 6 1 22417920 22418010 validated in-house developed bioinformatics analysis FLNC NM_001458 47 7 128498061 128498271 pipeline and Fabric software packages. Data quality is LEFTY2 NM_001172425 3 1 226127455 226127571 assessed to confirm it has a minimum coverage of 20X for SDHA NM_004168 14 5 254507 254621 >95% of targets of interest, TBX20 NM_001166220 6 7 35271111 35271192 Gene Specific Sequencing: PCR-based or NGS-based sequencing of entire coding region, intron/exon Low coverage (<20X) regions boundaries of the specified gene GENE TRANSCRIPT EXON CHROM EXON_START EXON_END Variant Specific Analysis: Sanger sequencing following CDC42 NM_001791 6 1 22417920 22418010 PCR amplification of the targeted variant(s) of the CFHR1 NM_002113 1 1 196788974 196789032 specified gene CFHR2 NM_005666 1 1 196913010 196913068 Deletion/Duplication Analysis: Copy number variant CFHR3 NM_021023 4 1 196757345 196757528 analysis of the gene by comparative genomic hybridization CFHR3 NM_021023 5 1 196759174 196759357 CORO1A NM_007074 11 16 30200180 30200285 Results: EFL1 NM_024580 7 15 82530647 82530862 Each test report includes a detailed interpretation of the FANCD2 NM_033084 14 3 10085512 10085548 genetic findings, the clinical significance of the esult,r and FANCD2 NM_033084 17 3 10091057 10091189 specific ecommendationsr for the clinical management and FANCD2 NM_033084 22 3 10106039 10106113 additional testing, if warranted. Results will be reported to IGLL1 NM_152855 2 22 23915723 23915772 the referring physician or health care provider as specified PLEKHM1 NM_014798 2 17 43559802 43559850 on the test requisition form. PLEKHM1 NM_014798 8 17 43527983 43528129 PLEKHM1 NM_014798 9 17 43522835 43523029 Please note: These regions represent the low coverage (<20X) regions identified during our test validation. For specific patient cases, these regions may vary slightly. Turn-Around Time: FBN1 Full Mutation Analysis: 81408 Gene panels: up to 6 weeks LDLR Gene Sequencing: 81406 Individual/custom gene sequencing: up to 6 weeks Marfan Syndrome and MFS Related Disorders Panel: Targeted analysis: up to 2 weeks 81405 x2, 81408 Deletion/Duplication analysis: up to 4 weeks RASopathy/Noonan Spectrum Disorders Panel: 81442 Short QT Syndrome Panel: 81403, 81406, 81479 x2 Thoracic Aortic Aneurysm Panel: 81410 CPT Codes: TTN Full Mutation Analysis: 81479 APOB (R3500Q/R3500W) Sequencing Analysis: 81401 Targeted variant analysis and deletion/duplication: Arrhythmogenic Right Ventricular Cardiomyopathy call for information. (ARVC) Panel, Dilated Cardiomyopathy (DCM) Panel, Please call 1-866-450-4198 for current pricing, insurance Hypertrophic Cardiomyopathy (HCM) Panel, Left preauthorization or with any billing questions. Ventricular Noncompaction (LVNC) Panel, Restrictive Cardiomyopathy (RCM) Panel: 81439 Shipping Instructions: Atrial Fibrillation (A Fib) Panel, Brugada Syndrome Please enclose test requisition with sample. All Panel, Congenital Heart Disease Panel, Heterotaxy information must be completed before sample can Panel, Long QT Syndrome Panel, Pulmonary Arterial be processed. Place samples in styrofoam mailer and ship at room temperature by overnight Hypertension (PAH) Panel: 81443 Federal Express to arrive Monday through Atrioventricular Block (AV Block) Panel: 81404, Saturday. 81405, 81406 Ship to: Comprehensive Arrhythmia Panel: 81413 Laboratory of Genetics and Genomics Catecholaminergic Polymorphic Ventricular 3333 Burnet Avenue NRB 1042 Tachycardia (CPVT) Panel: 81403, 81405, 81408 Cincinnati, OH 45229 Comprehensive Cardiomyopathy Panel: 81439 513-636-4474 Arrythmia Disorders: Panel Name # of Genes Genes Comprehensive Arrhythmia Panel ABCC9, ACTN2, AKAP9, ANK2, ANKRD1, BAG3, CACNA1C, CACNA2D1, 81 CACNB2, CALM1, CALM2, CALM3, CASQ2, CAV3, CDH2, CPT1A, CTNNA3, DES, DSC2, DSG2, DSP, EMD, FLNC, GATA4, GATA5, GATA6, GJA5, GNB5, GPD1L, GYG1, HCN4, JUP, KCNA5, KCND3, KCNE1, KCNE1L, KCNE2, KCNE3, KCNH2, KCNJ2, KCNJ5, KCNJ8, KCNK3, KCNQ1, KCNQ3, LDB3, LMNA, MYH6, MYH7, MYL4, NKX2-5, NOS1AP, NPPA, NUP155, PDLIM3, PKP2, PLN, PPA2, PRKAG2, RANGRF, RBM20, RYR2, SCN10A, SCN1B, SCN2B, SCN3B, SCN4B, SCN5A, SLC25A20, SLMAP, SNTA1, TBX5, TECRL, TGFB3, TMEM43, TNNI3, TNNI3K, TNNT2, TRDN, TRPM4, TTN Atrial Fibrillation (A Fib) Panel 28 ABCC9, CACNB2, GATA4, GATA6, GJA5,
Recommended publications
  • FLNC Missense Variants in Familial Noncompaction Cardiomyopathy

    FLNC Missense Variants in Familial Noncompaction Cardiomyopathy

    Cardiogenetics 2019; volume 9:8181 FLNC missense variants than 2 according to current echocardio- in familial noncompaction graphic criteria, or 2.3 on CMR.1,2 Correspondence: Jaap I. van Waning, Approximately 10% of patients diagnosed Department of Clinical Genetics, EE 2038, cardiomyopathy with NCCM have concurrent congenital Erasmus MC, POB 2040, 3000CA Rotterdam, heart defects (CHD).3,4 the Netherlands. Tel.: +3107038388 - Fax: +3107043072. Jaap I. van Waning,1 In 30-40% of cases diagnosed with E-mail: [email protected] Yvonne M. Hoedemaekers,2 NCCM a pathogenic variant can be identi- 2,3 4 Wouter P. te Rijdt, Arne I. Jpma, fied. Around 80% of these pathogenic vari- Acknowledgements: JVW was supported by a Daphne Heijsman,4 Kadir Caliskan,5 ants involve the same sarcomere genes, that grant from the Jaap Schouten Foundation. Elke S. Hoendermis,6 are the major causes for hypertrophic car- WPTR was supported by a Young Talent Program (CVON PREDICT) grant 2017T001 Tineke P. Willems,7 diomyopathy (HCM) and dilated cardiomy- - Dutch Heart Foundation. 8 opathy (DCM), in particular MYH7, Arthur van den Wijngaard, 5,6 3 MYBPC3 and TTN. Filamin C (FLNC) Albert Suurmeijer, Conflict of interest: the authors declare no plays a central role in muscle functioning Marjon A. van Slegtenhorst,1 potential conflict of interest. by maintaining the structural integrity of the Jan D.H. Jongbloed,2 muscle fibers. Pathogenic variants in FLNC Received for publication: 20 March 2019. Danielle F. Majoor-Krakauer,1 2 were found to be associated with a wide Revision received: 29 July 2019. Paul A.
  • The Cytoskeleton in Cell-Autonomous Immunity: Structural Determinants of Host Defence

    The Cytoskeleton in Cell-Autonomous Immunity: Structural Determinants of Host Defence

    Mostowy & Shenoy, Nat Rev Immunol, doi:10.1038/nri3877 The cytoskeleton in cell-autonomous immunity: structural determinants of host defence Serge Mostowy and Avinash R. Shenoy Medical Research Council Centre of Molecular Bacteriology and Infection (CMBI), Imperial College London, Armstrong Road, London SW7 2AZ, UK. e‑mails: [email protected] ; [email protected] doi:10.1038/nri3877 Published online 21 August 2015 Abstract Host cells use antimicrobial proteins, pathogen-restrictive compartmentalization and cell death in their defence against intracellular pathogens. Recent work has revealed that four components of the cytoskeleton — actin, microtubules, intermediate filaments and septins, which are well known for their roles in cell division, shape and movement — have important functions in innate immunity and cellular self-defence. Investigations using cellular and animal models have shown that these cytoskeletal proteins are crucial for sensing bacteria and for mobilizing effector mechanisms to eliminate them. In this Review, we highlight the emerging roles of the cytoskeleton as a structural determinant of cell-autonomous host defence. 1 Mostowy & Shenoy, Nat Rev Immunol, doi:10.1038/nri3877 Cell-autonomous immunity, which is defined as the ability of a host cell to eliminate an invasive infectious agent, is a first line of defence against microbial pathogens 1 . It relies on antimicrobial proteins, specialized degradative compartments and programmed host cell death 1–3 . Cell- autonomous immunity is mediated by tiered innate immune signalling networks that sense microbial pathogens and stimulate downstream pathogen elimination programmes. Recent studies on host– microorganism interactions show that components of the host cell cytoskeleton are integral to the detection of bacterial pathogens as well as to the mobilization of antibacterial responses (FIG.
  • Atlas Antibodies in Breast Cancer Research Table of Contents

    Atlas Antibodies in Breast Cancer Research Table of Contents

    ATLAS ANTIBODIES IN BREAST CANCER RESEARCH TABLE OF CONTENTS The Human Protein Atlas, Triple A Polyclonals and PrecisA Monoclonals (4-5) Clinical markers (6) Antibodies used in breast cancer research (7-13) Antibodies against MammaPrint and other gene expression test proteins (14-16) Antibodies identified in the Human Protein Atlas (17-14) Finding cancer biomarkers, as exemplified by RBM3, granulin and anillin (19-22) Co-Development program (23) Contact (24) Page 2 (24) Page 3 (24) The Human Protein Atlas: a map of the Human Proteome The Human Protein Atlas (HPA) is a The Human Protein Atlas consortium cell types. All the IHC images for Swedish-based program initiated in is mainly funded by the Knut and Alice the normal tissue have undergone 2003 with the aim to map all the human Wallenberg Foundation. pathology-based annotation of proteins in cells, tissues and organs expression levels. using integration of various omics The Human Protein Atlas consists of technologies, including antibody- six separate parts, each focusing on References based imaging, mass spectrometry- a particular aspect of the genome- 1. Sjöstedt E, et al. (2020) An atlas of the based proteomics, transcriptomics wide analysis of the human proteins: protein-coding genes in the human, pig, and and systems biology. mouse brain. Science 367(6482) 2. Thul PJ, et al. (2017) A subcellular map of • The Tissue Atlas shows the the human proteome. Science. 356(6340): All the data in the knowledge resource distribution of proteins across all eaal3321 is open access to allow scientists both major tissues and organs in the 3.
  • Screening for Copy Number Variation in Genes Associated with the Long QT Syndrome Clinical Relevance

    Screening for Copy Number Variation in Genes Associated with the Long QT Syndrome Clinical Relevance

    Journal of the American College of Cardiology Vol. 57, No. 1, 2011 © 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.08.621 Heart Rhythm Disorders Screening for Copy Number Variation in Genes Associated With the Long QT Syndrome Clinical Relevance Julien Barc, PHD,*‡§ François Briec, MD,*†‡§ Sébastien Schmitt, MD,ʈ Florence Kyndt, PharmD, PHD,*‡§ʈ Martine Le Cunff, BS,*‡§ Estelle Baron, BS,*‡§ Claude Vieyres, MD,¶ Frédéric Sacher, MD,# Richard Redon, PHD,*‡§ Cédric Le Caignec, MD, PHD,*‡§ʈ Hervé Le Marec, MD, PHD,*†‡§ Vincent Probst, MD, PHD,*†‡§ Jean-Jacques Schott, PHD*†‡§ Nantes, Angoulême, and Bordeaux, France Objectives The aim of this study was to investigate, in a set of 93 mutation-negative long QT syndrome (LQTS) probands, the frequency of copy number variants (CNVs) in LQTS genes. Background LQTS is an inherited cardiac arrhythmia characterized by a prolonged heart rate–corrected QT (QTc) interval as- sociated with sudden cardiac death. Recent studies suggested the involvement of duplications or deletions in the occurrence of LQTS. However, their frequency remains unknown in LQTS patients. Methods Point mutations in KCNQ1, KCNH2, and SCN5A genes were excluded by denaturing high-performance liquid chromatography or direct sequencing. We applied Multiplex Ligation-dependent Probe Amplification (MLPA) to detect CNVs in exons of these 3 genes. Abnormal exon copy numbers were confirmed by quantitative multiplex PCR of short fluorescent fragment (QMPSF). Array-based comparative genomic hybridization (array CGH) analysis was performed using Agilent Human Genome 244K Microarrays to further map the genomic rearrangements.
  • Defining Functional Interactions During Biogenesis of Epithelial Junctions

    Defining Functional Interactions During Biogenesis of Epithelial Junctions

    ARTICLE Received 11 Dec 2015 | Accepted 13 Oct 2016 | Published 6 Dec 2016 | Updated 5 Jan 2017 DOI: 10.1038/ncomms13542 OPEN Defining functional interactions during biogenesis of epithelial junctions J.C. Erasmus1,*, S. Bruche1,*,w, L. Pizarro1,2,*, N. Maimari1,3,*, T. Poggioli1,w, C. Tomlinson4,J.Lees5, I. Zalivina1,w, A. Wheeler1,w, A. Alberts6, A. Russo2 & V.M.M. Braga1 In spite of extensive recent progress, a comprehensive understanding of how actin cytoskeleton remodelling supports stable junctions remains to be established. Here we design a platform that integrates actin functions with optimized phenotypic clustering and identify new cytoskeletal proteins, their functional hierarchy and pathways that modulate E-cadherin adhesion. Depletion of EEF1A, an actin bundling protein, increases E-cadherin levels at junctions without a corresponding reinforcement of cell–cell contacts. This unexpected result reflects a more dynamic and mobile junctional actin in EEF1A-depleted cells. A partner for EEF1A in cadherin contact maintenance is the formin DIAPH2, which interacts with EEF1A. In contrast, depletion of either the endocytic regulator TRIP10 or the Rho GTPase activator VAV2 reduces E-cadherin levels at junctions. TRIP10 binds to and requires VAV2 function for its junctional localization. Overall, we present new conceptual insights on junction stabilization, which integrate known and novel pathways with impact for epithelial morphogenesis, homeostasis and diseases. 1 National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London SW7 2AZ, UK. 2 Computing Department, Imperial College London, London SW7 2AZ, UK. 3 Bioengineering Department, Faculty of Engineering, Imperial College London, London SW7 2AZ, UK. 4 Department of Surgery & Cancer, Faculty of Medicine, Imperial College London, London SW7 2AZ, UK.
  • Characterization of Pulmonary Arteriovenous Malformations in ACVRL1 Versus ENG Mutation Carriers in Hereditary Hemorrhagic Telangiectasia

    Characterization of Pulmonary Arteriovenous Malformations in ACVRL1 Versus ENG Mutation Carriers in Hereditary Hemorrhagic Telangiectasia

    © American College of Medical Genetics and Genomics ORIGINAL RESEARCH ARTICLE Characterization of pulmonary arteriovenous malformations in ACVRL1 versus ENG mutation carriers in hereditary hemorrhagic telangiectasia Weiyi Mu, ScM1, Zachary A. Cordner, MD, PhD2, Kevin Yuqi Wang, MD3, Kate Reed, MPH, ScM4, Gina Robinson, RN5, Sally Mitchell, MD5 and Doris Lin, MD, PhD5 Purpose: Pulmonary arteriovenous malformations (pAVMs) are mutation carriers to have pAVMs (P o 0.001) or multiple lesions major contributors to morbidity and mortality in hereditary (P = 0.03), and to undergo procedural intervention (P = 0.02). hemorrhagic telangiectasia (HHT). Mutations in ENG and ACVRL1 Additionally, pAVMs in ENG carriers were more likely to exhibit underlie the vast majority of clinically diagnosed cases. The aims of bilateral lung involvement and growth over time, although this did this study were to characterize and compare the clinical and not reach statistical significance. The HHT severity score was morphologic features of pAVMs between these two genotype significantly higher in ENG than in ACVRL1 (P = 0.02). groups. Conclusion: The propensity and multiplicity of ENG-associated Methods: Sixty-six patients with HHT and affected family pAVMs may contribute to the higher disease severity in this members were included. Genotype, phenotypic data, and imaging genotype, as reflected by the HHT severity score and the frequency were obtained from medical records. Morphologic features of of interventional procedures. pAVMs were analyzed using computed tomography angiography. Genet Med HHT symptoms, pAVM imaging characteristics, frequency of advance online publication 19 October 2017 procedural intervention, and HHT severity scores were compared Key Words: ACVRL1; ENG; genotype-phenotype correlation; between ENG and ACVRL1 genotype groups.
  • List of Genes Associated with Sudden Cardiac Death (Scdgseta) Gene

    List of Genes Associated with Sudden Cardiac Death (Scdgseta) Gene

    List of genes associated with sudden cardiac death (SCDgseta) mRNA expression in normal human heart Entrez_I Gene symbol Gene name Uniprot ID Uniprot name fromb D GTEx BioGPS SAGE c d e ATP-binding cassette subfamily B ABCB1 P08183 MDR1_HUMAN 5243 √ √ member 1 ATP-binding cassette subfamily C ABCC9 O60706 ABCC9_HUMAN 10060 √ √ member 9 ACE Angiotensin I–converting enzyme P12821 ACE_HUMAN 1636 √ √ ACE2 Angiotensin I–converting enzyme 2 Q9BYF1 ACE2_HUMAN 59272 √ √ Acetylcholinesterase (Cartwright ACHE P22303 ACES_HUMAN 43 √ √ blood group) ACTC1 Actin, alpha, cardiac muscle 1 P68032 ACTC_HUMAN 70 √ √ ACTN2 Actinin alpha 2 P35609 ACTN2_HUMAN 88 √ √ √ ACTN4 Actinin alpha 4 O43707 ACTN4_HUMAN 81 √ √ √ ADRA2B Adrenoceptor alpha 2B P18089 ADA2B_HUMAN 151 √ √ AGT Angiotensinogen P01019 ANGT_HUMAN 183 √ √ √ AGTR1 Angiotensin II receptor type 1 P30556 AGTR1_HUMAN 185 √ √ AGTR2 Angiotensin II receptor type 2 P50052 AGTR2_HUMAN 186 √ √ AKAP9 A-kinase anchoring protein 9 Q99996 AKAP9_HUMAN 10142 √ √ √ ANK2/ANKB/ANKYRI Ankyrin 2 Q01484 ANK2_HUMAN 287 √ √ √ N B ANKRD1 Ankyrin repeat domain 1 Q15327 ANKR1_HUMAN 27063 √ √ √ ANKRD9 Ankyrin repeat domain 9 Q96BM1 ANKR9_HUMAN 122416 √ √ ARHGAP24 Rho GTPase–activating protein 24 Q8N264 RHG24_HUMAN 83478 √ √ ATPase Na+/K+–transporting ATP1B1 P05026 AT1B1_HUMAN 481 √ √ √ subunit beta 1 ATPase sarcoplasmic/endoplasmic ATP2A2 P16615 AT2A2_HUMAN 488 √ √ √ reticulum Ca2+ transporting 2 AZIN1 Antizyme inhibitor 1 O14977 AZIN1_HUMAN 51582 √ √ √ UDP-GlcNAc: betaGal B3GNT7 beta-1,3-N-acetylglucosaminyltransfe Q8NFL0
  • Key Pathways Involved in Prostate Cancer Based on Gene Set Enrichment Analysis and Meta Analysis

    Key Pathways Involved in Prostate Cancer Based on Gene Set Enrichment Analysis and Meta Analysis

    Key pathways involved in prostate cancer based on gene set enrichment analysis and meta analysis Q.Y. Ning1, J.Z. Wu1, N. Zang2, J. Liang3, Y.L. Hu2 and Z.N. Mo4 1Department of Infection, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China 2The Medical Scientific Research Centre, Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China 3Department of Biology Technology, Guilin Medical University, Guilin, Guangxi Zhuang Autonomous Region, China 4Department of Urology, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China Corresponding authors: Y.L. Hu / Z.N. Mo E-mail: [email protected] / [email protected] Genet. Mol. Res. 10 (4): 3856-3887 (2011) Received June 7, 2011 Accepted October 14, 2011 Published December 14, 2011 DOI http://dx.doi.org/10.4238/2011.December.14.10 ABSTRACT. Prostate cancer is one of the most common male malignant neoplasms; however, its causes are not completely understood. A few recent studies have used gene expression profiling of prostate cancer to identify differentially expressed genes and possible relevant pathways. However, few studies have examined the genetic mechanics of prostate cancer at the pathway level to search for such pathways. We used gene set enrichment analysis and a meta-analysis of six independent studies after standardized microarray preprocessing, which increased concordance between these gene datasets. Based on gene set enrichment analysis, there were 12 down- and 25 up-regulated mixing pathways in more than two tissue datasets, while there were two down- and two up-regulated mixing pathways in three cell datasets.
  • Heterotrimeric Go Protein Links Wnt-Frizzled Signaling with Ankyrins to Regulate the Neuronal Microtubule Cytoskeleton Anne-Marie Lüchtenborg1,2, Gonzalo P

    Heterotrimeric Go Protein Links Wnt-Frizzled Signaling with Ankyrins to Regulate the Neuronal Microtubule Cytoskeleton Anne-Marie Lüchtenborg1,2, Gonzalo P

    © 2014. Published by The Company of Biologists Ltd | Development (2014) 141, 3399-3409 doi:10.1242/dev.106773 RESEARCH ARTICLE Heterotrimeric Go protein links Wnt-Frizzled signaling with ankyrins to regulate the neuronal microtubule cytoskeleton Anne-Marie Lüchtenborg1,2, Gonzalo P. Solis1, Diane Egger-Adam2, Alexey Koval1, Chen Lin1,2, Maxime G. Blanchard1, Stephan Kellenberger1 and Vladimir L. Katanaev1,2,* ABSTRACT The evolutionarily conserved Wg pathway is important for Drosophila neuromuscular junctions (NMJs) represent a powerful numerous developmental programs and cellular processes (Logan model system with which to study glutamatergic synapse formation and Nusse, 2004). In the nervous system of Drosophila,Wg and remodeling. Several proteins have been implicated in these signaling is involved in the formation of neuromuscular junctions processes, including components of canonical Wingless (Drosophila (NMJs) (Packard et al., 2002; Miech et al., 2008). Being a Wnt1) signaling and the giant isoforms of the membrane-cytoskeleton glutamatergic synapse, the Drosophila NMJ provides a useful linker Ankyrin 2, but possible interconnections and cooperation experimental model with which to study mammalian central between these proteins were unknown. Here, we demonstrate that nervous system synapses, their formation and remodeling (Collins the heterotrimeric G protein Go functions as a transducer of Wingless- and DiAntonio, 2007). The Drosophila NMJ is a beads-on-a-string- Frizzled 2 signaling in the synapse. We identify Ankyrin 2 as a target like structure that is formed at the axon terminus and is composed of – – of Go signaling required for NMJ formation. Moreover, the Go-ankyrin distinct circular structures the synaptic boutons which contain interaction is conserved in the mammalian neurite outgrowth pathway.
  • Tumor Promoting Effect of BMP Signaling in Endometrial Cancer

    Tumor Promoting Effect of BMP Signaling in Endometrial Cancer

    International Journal of Molecular Sciences Article Tumor Promoting Effect of BMP Signaling in Endometrial Cancer Tomohiko Fukuda 1,* , Risa Fukuda 1, Kohei Miyazono 1,2,† and Carl-Henrik Heldin 1,*,† 1 Science for Life Laboratory, Department of Medical Biochemistry and Microbiology, Box 582, Uppsala University, SE-751 23 Uppsala, Sweden; [email protected] (R.F.); [email protected] (K.M.) 2 Department of Molecular Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan * Correspondence: [email protected] (T.F.); [email protected] (C.-H.H.); Tel.: +46-18-4714738 (T.F.); +46-18-4714738 (C.-H.H.) † These authors contributed equally to this work. Abstract: The effects of bone morphogenetic proteins (BMPs), members of the transforming growth factor-β (TGF-β) family, in endometrial cancer (EC) have yet to be determined. In this study, we analyzed the TCGA and MSK-IMPACT datasets and investigated the effects of BMP2 and of TWSG1, a BMP antagonist, on Ishikawa EC cells. Frequent ACVR1 mutations and high mRNA expressions of BMP ligands and receptors were observed in EC patients of the TCGA and MSK-IMPACT datasets. Ishikawa cells secreted higher amounts of BMP2 compared with ovarian cancer cell lines. Exogenous BMP2 stimulation enhanced EC cell sphere formation via c-KIT induction. BMP2 also induced EMT of EC cells, and promoted migration by induction of SLUG. The BMP receptor kinase inhibitor LDN193189 augmented the growth inhibitory effects of carboplatin. Analyses of mRNAs of several BMP antagonists revealed that TWSG1 mRNA was abundantly expressed in Ishikawa cells.
  • Diagnostic Test: OBESITÀ GENETICHE MENDELIANE

    Diagnostic Test: OBESITÀ GENETICHE MENDELIANE

    Diagnostic test: OBESITÀ GENETICHE MENDELIANE MENDELIAN OBESITY Panel / Illumina Custom panel, Nextera Enrichment Technology / Coding exons and flanking regions of genes List of gene(s) and disease(s) tested: ALMS1, ARL6, BBIP1, BBS1, BBS10, BBS12, BBS2, BBS4, BBS5, BBS7, BBS9, C8orf37, CARTPT, CEP19, CEP290, DYRK1B, GNAS, HDAC8, IFT172, IFT27, INPP5E, INSR, KSR2, LEP, LEPR, LZTFL1, MC3R, MC4R, MCHR1, MEGF8, MKKS, MKS1, NR0B2, PCSK1, PHF6, POMC, PPARG, PPP1R3A, RAB23, SDCCAG8, SH2B1, SIM1, TRIM32, TTC8, UCP3, VPS13B, WDPCP ORPHA:98267 Obesità non sindromica genetica Obesità sindromica Tabella Elenco delle forme di OBESITÀ GENETICHE MENDELIANE e la loro eziologia genetica Phenotype OMIM# Gene OMIM# Phenotype Gene Alstrom syndrome 203800 ALMS1 606844 Bardet-Biedl syndrome 3 600151 ARL6 608845 Bardet-Biedl syndrome 18 615995 BBIP1 613605 Bardet-Biedl syndrome 1 209900 BBS1 209901 Bardet-Biedl syndrome 10 615987 BBS10 610148 Bardet-Biedl syndrome 12 615989 BBS12 610683 Bardet-Biedl syndrome 2 615981 BBS2 606151 Bardet-Biedl syndrome 4 615982 BBS4 600374 Bardet-Biedl syndrome 5 615983 BBS5 603650 Bardet-Biedl syndrome 7 615984 BBS7 607590 Bardet-Biedl syndrome 21 617406 C8orf37 614477 Obesity, severe HGMD CARTPT 602606 Morbid obesity and spermatogenic failure; Bardet-Biedl syndrome; Morbid obesity 615703; HGMD CEP19 615586 Bardet-Biedl syndrome 14 615991 CEP290 610142 Abdominal obesity-metabolic syndrome 3 615812 DYRK1B 604556 Pseudohypoparathyroidism Ia; Pseudohypoparathyroidism Ic 103580; 612462 GNAS 139320 Cornelia de Lange syndrome 5 300882
  • Identification of an FHL1 Protein Complex Containing Gamma-Actin and Non-Muscle Myosin IIB by Analysis of Protein-Protein Interactions

    Identification of an FHL1 Protein Complex Containing Gamma-Actin and Non-Muscle Myosin IIB by Analysis of Protein-Protein Interactions

    Identification of an FHL1 Protein Complex Containing Gamma-Actin and Non-Muscle Myosin IIB by Analysis of Protein-Protein Interactions Lili Wang1*, Jianing Miao1, Lianyong Li2,DiWu1, Yi Zhang1, Zhaohong Peng1, Lijun Zhang2, Zhengwei Yuan1, Kailai Sun3 1 Key Laboratory of Health ~Ministry for Congenital Malformation, Shengjing Hospital, China Medical University, Shenyang, China, 2 Department of Pediatric Surgery, Shengjing Hospital, China Medical University, Shenyang, China, 3 Department of Medical Genetics, China Medical University, Shenyang, China Abstract FHL1 is multifunctional and serves as a modular protein binding interface to mediate protein-protein interactions. In skeletal muscle, FHL1 is involved in sarcomere assembly, differentiation, growth, and biomechanical stress. Muscle abnormalities may play a major role in congenital clubfoot (CCF) deformity during fetal development. Thus, identifying the interactions of FHL1 could provide important new insights into its functional role in both skeletal muscle development and CCF pathogenesis. Using proteins derived from rat L6GNR4 myoblastocytes, we detected FHL1 interacting proteins by immunoprecipitation. Samples were analyzed by liquid chromatography mass spectrometry (LC-MS). Dynamic gene expression of FHL1 was studied. Additionally, the expression of the possible interacting proteins gamma-actin and non- muscle myosin IIB, which were isolated from the lower limbs of E14, E15, E17, E18, E20 rat embryos or from adult skeletal muscle was analyzed. Potential interacting proteins isolated from E17 lower limbs were verified by immunoprecipitation, and co-localization in adult gastrocnemius muscle was visualized by fluorescence microscopy. FHL1 expression was associated with skeletal muscle differentiation. E17 was found to be the critical time-point for skeletal muscle differentiation in the lower limbs of rat embryos.